Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425204
Status:
COMPLETED
Last Update Posted:
2008-09-15
First Post:
2007-01-18
Brief Title:
Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Multi-Center Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multi-center open-label extended treatment clinical trial examining the safety of administering multiple does of panitumumab by intravenous iv infusion to patients who have previously received panitumumab and benefited from treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Abgenix Protocol No ABX-0311 | None | None | None |